Merck (NYSE:MRK) reported disappointing results of a study of an investigational heart drug at an American Heart Association event over the weekend.
Merck said the study of vorapaxar, which is designed to prevent thrombosis and other cardiovascular events, failed to meet a primary endpoint of in a study in patients with acute coronary syndrome.
The drug did not result in a statistically significant reduction in the first occurrence of any component of the composite of cardiovascular death, myocardial infarction, stroke, recurrent ischemia and urgent coronary revascularization, when added to the standard of care.
And today, Sanofi's (NASDAQ:SNY) Genzyme said a phase 3 trial of its multiple sclerosis treatment Lemtrada showed the drug met both primary endpoints.
The drug reduced relapse rated as well as worsening of disability in a study as compared to Pfizer's (NYSE:PFE) Rebif.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.